LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced a quarterly dividend on Monday, October 30th, Wall Street Journal reports. Shareholders of record on Wednesday, November 22nd will be given a dividend of 0.055 per share by the medical instruments supplier on Thursday, December 7th. This represents a $0.22 annualized dividend and a yield of 0.64%. The ex-dividend date of this dividend is Tuesday, November 21st.

Shares of LeMaitre Vascular (NASDAQ LMAT) opened at $34.44 on Thursday. LeMaitre Vascular has a 12 month low of $19.82 and a 12 month high of $39.88. The firm has a market cap of $660.40, a price-to-earnings ratio of 44.52, a price-to-earnings-growth ratio of 2.72 and a beta of 0.55.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Thursday, October 26th. The medical instruments supplier reported $0.25 earnings per share for the quarter, beating the consensus estimate of $0.20 by $0.05. LeMaitre Vascular had a net margin of 15.81% and a return on equity of 16.16%. The firm had revenue of $24.80 million during the quarter, compared to analyst estimates of $25.49 million. During the same quarter in the previous year, the firm earned $0.17 earnings per share. The firm’s revenue for the quarter was up 6.9% compared to the same quarter last year. sell-side analysts expect that LeMaitre Vascular will post 0.84 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was first published by Watch List News and is owned by of Watch List News. If you are accessing this report on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this report can be read at https://www.watchlistnews.com/lemaitre-vascular-inc-lmat-to-go-ex-dividend-on-november-21st/1706601.html.

In related news, Chairman George W. Lemaitre sold 40,000 shares of the company’s stock in a transaction dated Friday, August 25th. The shares were sold at an average price of $33.89, for a total value of $1,355,600.00. Following the completion of the sale, the chairman now owns 3,390,508 shares of the company’s stock, valued at $114,904,316.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider David B. Roberts sold 4,123 shares of the company’s stock in a transaction dated Monday, November 6th. The stock was sold at an average price of $32.14, for a total transaction of $132,513.22. Following the completion of the sale, the insider now directly owns 24,482 shares of the company’s stock, valued at approximately $786,851.48. The disclosure for this sale can be found here. Insiders have sold 150,806 shares of company stock valued at $5,346,329 in the last 90 days. Insiders own 23.70% of the company’s stock.

LeMaitre Vascular announced that its board has authorized a stock repurchase plan on Thursday, July 27th that allows the company to buyback $7.50 million in shares. This buyback authorization allows the medical instruments supplier to reacquire up to 1.4% of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s board of directors believes its shares are undervalued.

Several analysts have weighed in on the stock. Zacks Investment Research lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Friday, November 10th. Stifel Nicolaus restated a “buy” rating on shares of LeMaitre Vascular in a research report on Sunday, October 29th. Canaccord Genuity lowered their price target on shares of LeMaitre Vascular from $30.00 to $29.00 and set a “hold” rating for the company in a research report on Friday, October 27th. Benchmark Co. lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Friday, October 27th. Finally, First Analysis lowered shares of LeMaitre Vascular from an “overweight” rating to an “equal weight” rating and set a $34.00 price target for the company. in a research report on Friday, October 27th. Seven research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. LeMaitre Vascular currently has a consensus rating of “Hold” and an average target price of $32.20.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.

Dividend History for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.